13F Holdings
中文EN

ALLO Allogene Therapeutics, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1737287 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY-26.7%
TTM net income YoY22.1%
TTM EPS YoY36.8%
Revenue 3-yr CAGR-91.7%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,241,813.6%
Net margin-1,170,863.6%
FCF margin-913,609.1%
EBITDA margin-1,179,818.2%

Returns

ROE-55.1%
ROA-43.2%
ROIC (approx.)-57.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets23.1%
Debt / equity0.00x
Current ratio8.54x
Interest coverage-1,509.39x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue3,154.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$0$22,000$95,000$156,000$114.09M
R&D expense$150.15M$192.30M$242.91M$256.39M$220.18M
SG&A expense$56.78M$65.20M$71.67M$79.31M$74.11M
Operating income-$209.31M-$273.20M-$327.74M-$335.54M-$180.19M
Interest expense$1.07M$181,000$0——
Pretax income-$190.89M-$257.15M-$327.26M—-$257.00M
Income tax$0$443,000$0$0$0
Net income-$190.89M-$257.59M-$327.26M-$340.41M-$182.05M
EBITDA-$196.96M-$259.56M-$313.54M-$321.24M-$169.69M
EPS (basic)-0.87-1.32-2.09-2.38-1.34
EPS (diluted)-0.87-1.32-2.09-2.38-1.34
Dividends declared per share0.000.000.000.000.00
Weighted avg. shares (diluted)220.62M194.81M156.93M143.15M135.82M
Balance sheet
Cash & equivalents$51.69M$85.51M$93.45M$72.20M$183.61M
Short-term investments$198.52M$217.26M$365.54M$455.42M$283.99M
Current assets$257.75M$303.39M$459.12M$528.82M$471.32M
PP&E, net$72.84M$86.06M$99.48M$112.84M$122.99M
Total assets$415.90M$548.71M$642.84M$821.58M$1.05B
Current liabilities$32.51M$35.52M$37.08M$53.73M$47.91M
Total liabilities$123.36M$126.53M$130.60M$154.70M$125.63M
Shareholders' equity$292.54M$422.18M$512.23M$666.88M$925.20M
Shares outstanding229.41M212.21M168.64M144.44M142.62M
Cash flow statement
Operating cash flow-$149.25M-$200.30M-$237.73M-$220.52M-$184.81M
Capital expenditure$386,000$694,000$1.52M$5.19M$21.45M
Free cash flow-$149.63M-$200.99M-$239.25M-$225.71M-$206.26M
Investing cash flow$95.56M$75.69M$163.29M$106.16M$163.66M
Financing cash flow$30.16M$116.67M$95.69M$2.95M$11.96M
Depreciation & amortization$12.36M$13.64M$14.20M$14.30M$10.50M
Stock-based compensation$37.64M$51.74M$65.95M$83.60M$80.82M

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.